332 related articles for article (PubMed ID: 17245364)
1. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Kukreja RC
Br J Pharmacol; 2007 Mar; 150(5):538-40. PubMed ID: 17245364
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Rossoni G; Manfredi B; De Gennaro Colonna V; Berti M; Guazzi M; Berti F
Br J Pharmacol; 2007 Mar; 150(5):567-76. PubMed ID: 17245365
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
5. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
6. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
9. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
10. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
11. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Hallén K; Wiklund NP; Gustafsson LE
Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
13. Is vardenafil "noninferior" or superior to sildenafil in the management of erectile dysfunction? Revisiting the biochemical, physiological, and clinical evidence.
Traish A; Kim N
J Sex Med; 2008 Jul; 5(7):1762-8; discussion 1768-9. PubMed ID: 18221281
[No Abstract] [Full Text] [Related]
14. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
15. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
16. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
Montorsi F; Corbin J; Phillips S
J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Agarwal P; Sander GE; Giles TD
Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
[No Abstract] [Full Text] [Related]
18. Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart.
Kukreja R; Salloum F; Xi L
Int J Impot Res; 2007; 19(2):226-7. PubMed ID: 17136101
[No Abstract] [Full Text] [Related]
19. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.
Salloum FN; Takenoshita Y; Ockaili RA; Daoud VP; Chou E; Yoshida K; Kukreja RC
J Mol Cell Cardiol; 2007 Feb; 42(2):453-8. PubMed ID: 17157308
[TBL] [Abstract][Full Text] [Related]
20. The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues.
Aziz MT; Mostafa T; Atta H; Rashed L; Marzouk SA; Obaia EM; Sabry D; Hassouna AA; El-Shehaby AM; Aziz AT
J Sex Med; 2008 Jul; 5(7):1636-45. PubMed ID: 18208506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
